The network is led by principle investigators Jan Friedman MD PhD and Michael Hayden MD PhD, supported by experienced professionals Shelin Adam, Co-ordinator and Lesley Phillips PhD, Business Manager, who are available to assist members. Our two leaders have experience leading innovative initiatives and have outstanding expertise in genomics research. The staff is experienced in genetics research and business management respectively.

Jan Friedman, MD, PhD, is Professor of Medical Genetics at the University of BC and Head, Genetics, Child & Family Research Institute. He served as Head of the UBC Department of Medical Genetics from 1989 to 1999 and has held leadership positions in international scientific and professional societies, including the founding presidency of the Association of Professors of Human and Medical Genetics, the presidency of the Canadian College of Medical Geneticists, and the presidency of the Teratology Society. He is project leader of the CFI-funded “Canadian Molecular Cytogenetics Platform” and co-leader of the Genome Canada/Genome BC project, “Genomic Tools for Diagnosis and Evaluation of Mental Retardation”. He is an author of more than 160 peer-reviewed research papers and six books.

Michael Hayden, MD, PhD, has led and managed highly successful scientific networks, including the Canadian Genetic Diseases Network that was recognized as a model network by the NCE program, and others involving successful collaboration with industry. As Director and Senior Scientist of the Centre for Molecular Medicine and Therapeutics, Child & Family research Institute, Dr. Hayden has led a highly successful, international and self-sustaining scientific enterprise with a track record for generating support for research. He is currently Professor of Medical Genetics at the University of BC and is author of over 400 peer-reviewed publications. He holds a Tier 1 Canada Research Chair and is a University Killam Professor.

Lesley Phillips PhD has held senior roles in business development, including as Senior Director, Business Development, Angiotech Pharmaceuticals where she spear-headed in-licensing and out-licensing strategies for drugs and technologies. She was also Director, New Business Opportunities for Cubist Pharmaceuticals and Alliance Manager at TerraGen Discovery, where she initiated and executed out-licensing of technology platforms, negotiated and managed key contracts and supported M&A. Earlier in her career, she headed a marketing program for the UK BioIndustry Association and was a scientific manager at Astra Zeneca, Novo Nordisk and Xenova Discovery. She has a Ph.D. in natural product discovery from Warwick.

Shelin Adam MSc is a genetic counselor and researcher. She has clinical experience in genetic and psychological counseling, specializing in adult-onset disorders. Shelin also has extensive experience in research, having been coordinator of the Canadian Collaborative Study on Predictive Testing for Huntington Disease. Recently, she has been involved in a study on idiopathic mental retardation using microArray Comparative Genomic Hybridization technology. She has co-authored a wide range of publications, as well as made a number of oral presentations at peer meetings and conventions.